Google Maps

NCT07740187

Overview

NCT ID: NCT07740187
Lead Sponsor: WeNatalINDUSTRY
Official Title: A Clinical Trial to Evaluate the Effects of a Supplement on Markers of Female Fertility
Brief Summary: This study evaluates the effects of a daily dietary supplement (WeNatal For Her) on markers of female fertility, reproductive health, and sexual health over three menstrual cycles. Forty female participants who are currently trying to conceive will take three capsules of the supplement each morning with their first meal.

The study is a single-arm, unblinded hybrid trial. Participants will complete questionnaires at Baseline and on Days 2-5 of Cycles 1, 2, and 3, and will attend a local Labcorp location for blood draws at Baseline and at Cycle 3. Primary outcomes include blood-based biomarkers of female fertility (e.g., AMH, FSH, Estradiol), while secondary outcomes capture self-reported perceptions of reproductive health, energy levels, mood, and overall well-being.
Conditions: Female Infertility

Status and Timeline

Status: Completed
Last Update Posted: Jul 31, 2026Actual
Start Date: Apr 15, 2025Actual
Primary Completion Date: Feb 12, 2026Actual
Completion Date

Participation Criteria

Ages Eligible for Study: Adult (18-64)
Sexes Eligible for Study: All
Accepts Healthy Volunteers?: Yes
Eligibility Criteria: Inclusion Criteria:

Be female.

Be aged 18-45.

In the past three menstrual cycles, has experienced issues with all of the following: Low energy levels and fatigue

Bloating

Breast tenderness

Irritability or mood swings.

Currently trying to conceive.

Anyone who is generally healthy - does not live with any uncontrolled chronic disease.

Not planning on introducing any products or any new forms of prescription medication or supplements that target female fertility for the study duration.

Has a regular menstrual cycle between 21 and 35 days in length and is able to predict the dates of their upcoming periods.

Resides in the United States.

Not currently partaking in another research study and will not be partaking in any other research study for the next three menstrual cycles and at any point during this study's duration.

Willing to avoid all other prenatal vitamins for the duration of this study.

Exclusion Criteria:

Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.

Anyone with any allergies or sensitivities to any of the study product ingredients.

Any women who are currently pregnant or breastfeeding.

Anyone taking anticoagulant or "blood thinning" medication.

Anyone taking bisphosphonates or other prescription medications for osteoporosis.

Anyone taking chemotherapy medication.

Anyone diagnosed with hemochromatosis or elevated iron levels.

Anyone who drinks heavily (i.e. eight or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men).

Anyone unwilling to follow the study protocol.

Anyone with a history of substance abuse.

Anyone who is currently a smoker or has been a smoker in the past three months.

Anyone who has stopped using hormonal birth control less than six months prior to starting the study.

Anyone previously diagnosed with premenstrual dysphoric disorder (PMDD), endometriosis, or any cancer of the reproductive system.

Anyone who is peri- or post-menopausal.

Study Plan

Study Type: Interventional
Phase: Not Applicable
Enrollment: 40Actual
Primary Purpose: Treatment
Allocation: N/A
Interventional Model: Single Group Assignment
Masking: None (Open Label)

Contacts and Locations

Central Contacts: No data available
Locations: Citruslabs

Overview

Status and Timeline

Participation Criteria

Study Plan

Contacts and Locations

Similar Studies